Several other research analysts have also weighed in on NVS. UBS Group reissued a neutral rating on shares of Novartis in a research report on Monday, January 15th. Nord/LB reissued a neutral rating on shares of Novartis in a research report on Tuesday, January 2nd. Barclays lowered Novartis from an equal weight rating to an underweight rating in a research report on Wednesday, October 25th. Leerink Swann upped their price target on Novartis from $89.00 to $91.00 and gave the company a market perform rating in a research report on Monday, October 23rd. Finally, Zacks Investment Research lowered Novartis from a buy rating to a hold rating in a research report on Thursday, September 21st. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $85.32.
Shares of Novartis (NVS) traded up $0.53 during trading on Thursday, hitting $86.94. The stock had a trading volume of 770,400 shares, compared to its average volume of 1,047,900. The firm has a market capitalization of $226,910.00, a price-to-earnings ratio of 30.94, a PEG ratio of 2.33 and a beta of 0.74. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32. Novartis has a 12 month low of $69.53 and a 12 month high of $87.29.
Novartis (NYSE:NVS) last announced its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.04. The company had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. Novartis had a return on equity of 15.77% and a net margin of 13.73%. Novartis’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.23 earnings per share. equities analysts anticipate that Novartis will post 4.79 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. WFG Advisors LP boosted its stake in shares of Novartis by 38.1% during the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after acquiring an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new stake in shares of Novartis during the 3rd quarter worth about $106,000. Cable Hill Partners LLC boosted its stake in shares of Novartis by 588.8% during the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after acquiring an additional 1,107 shares in the last quarter. Harding Loevner LP bought a new stake in shares of Novartis during the 2nd quarter worth about $146,000. Finally, Sawyer & Company Inc bought a new stake in shares of Novartis during the 4th quarter worth about $183,000. Hedge funds and other institutional investors own 10.85% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.truebluetribune.com/2018/01/22/novartis-nvs-stock-rating-reaffirmed-by-jpmorgan-chase-co.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.